| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/09/1995 | DE4325900A1 Trisubstituted pyrimido[5,4-d]pyrimidines for the modulation of multi-drug resistance, medicaments containing these compounds and processes for their production |
| 02/09/1995 | CA2168262A1 Methods of enhancing opiate analgesic potency or detoxifying an opiate addict |
| 02/08/1995 | EP0637241A1 Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic |
| 02/08/1995 | EP0637237A1 Calcium receptor-active molecules |
| 02/08/1995 | EP0637203A1 Regulation of the immune system |
| 02/08/1995 | CN1098286A PH-triggered osmotic bursting delivery devices |
| 02/07/1995 | US5387685 Bicyclic amines; resensitize multiple drug resistant cells to chemotherapeutic agents |
| 02/07/1995 | US5387612 Administering title compound or salt; memory disorders |
| 02/07/1995 | CA1334281C Emulsion for parenteral administration |
| 02/03/1995 | CA2129179A1 Trisubstituted pyrimido[5,4-d]pyrimidines for modulating multi-drug resistance, pharmaceutical compositions containing these compounds and processes for their preparation |
| 02/02/1995 | WO1995003335A1 Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
| 02/02/1995 | WO1995003036A1 Anti-angiogenic compositions and methods of use |
| 02/02/1995 | WO1994027583A3 Apoptosis inhibitors for treating neurodegenerative diseases |
| 02/02/1995 | DE3348444C2 Analgesic and antiinflammatory compositions |
| 02/02/1995 | CA2472404A1 Combination of stent and anti-angiogenic factor |
| 02/02/1995 | CA2468375A1 Anti-angiogenic compositions, uses and methods |
| 02/02/1995 | CA2168096A1 Inhibitors of alternative alleles of genes as a basis for cancer therapeutic agents |
| 02/01/1995 | EP0636631A1 Platinum complex and antineoplastic agent |
| 02/01/1995 | EP0636378A1 Absorbable composite materials for use in the treatment of periodontal disease |
| 02/01/1995 | EP0636027A1 Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy |
| 01/31/1995 | US5385941 Salts/ion pairs of non-steroidal anti-inflammatory drugs in various dosage forms |
| 01/31/1995 | US5385939 Preventing the axial elongation myopia in the eye by administering a gama-aminobutyric acid receptor antagonist |
| 01/31/1995 | US5385938 application of mixtures containing hydroxyacetic acid(or its salts) to skin |
| 01/31/1995 | US5385903 Pharmaceutical agent for treatment of withdrawal symptoms |
| 01/31/1995 | CA1334168C Antiglaucoma compositions containing combinations of .alpha.-2 agonists and .beta. blockers |
| 01/26/1995 | WO1995002420A2 Prodrugs of protein tyrosine kinase inhibitors |
| 01/26/1995 | WO1995002413A1 Suppression of inhibitors |
| 01/26/1995 | WO1995002409A2 Use of vitamin d and derivatives thereof for the manufacture of a medicament for protection against neuron loss |
| 01/26/1995 | DE4324877A1 Novel therapeutic mixtures, based on the prevention of intracellular Ca<2+>i overloading and Ca<2+>i independent influencing of the intracellular pHi of immunocompetent cells |
| 01/26/1995 | DE4320878A1 Considerable improvements in immunotherapy and transplantation of bone marrow and organs |
| 01/26/1995 | CA2167153A1 Prodrugs of protein tyrosine kinase inhibitors |
| 01/25/1995 | EP0635272A1 Liquid absorbable copolymers for parenteral applications |
| 01/25/1995 | EP0634933A1 Compositions of platelet activating factor antagonists and methods of treating interleukin-2 induced lung injury therewith |
| 01/25/1995 | EP0634932A1 Method for reducing intraocular pressure in the mammalian eye by administration of muscarinic antagonists |
| 01/25/1995 | EP0634896A1 Evaluation and treatment of patients with progressive immunosuppression |
| 01/24/1995 | US5384408 Nervous system disorders such as Alzheimer*s and senility |
| 01/24/1995 | US5384128 Nontoxic, nonionic surfactants and hypophilic-lipophilic balance number |
| 01/24/1995 | US5383848 Iontophoretic administration of drugs |
| 01/21/1995 | CA2128361A1 Liquid absorbable copolymers for parenteral applications |
| 01/19/1995 | WO1995002057A1 Protein tyrosine kinase and ligands thereof |
| 01/19/1995 | WO1995001802A1 Growth differentiation factor-7 |
| 01/19/1995 | WO1995001792A1 H2 antagonist-antihistamine combinations |
| 01/19/1995 | WO1995001773A1 Stimulation of tanning by dna fragments |
| 01/19/1995 | CA2165778A1 Growth differentiation factor-7 |
| 01/18/1995 | EP0634401A1 MDR reversal agents |
| 01/18/1995 | EP0634175A1 Pharmaceutical combination, containing a renin-angiotensin-system inhibitor and an endothelin antagonist |
| 01/18/1995 | EP0633887A1 Calanolide antiviral compounds, compositions and uses thereof |
| 01/18/1995 | EP0633789A1 Wound dressing, wound plaster or carrier matrix |
| 01/18/1995 | EP0633781A1 Compositions and methods for treating benign prostatic hypertrophy |
| 01/18/1995 | EP0633772A1 Medicament against cardiac circulatory diseases |
| 01/18/1995 | EP0633767A1 Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| 01/18/1995 | EP0633764A1 Skin care method and composition |
| 01/17/1995 | CA2128160A1 Cation-complexed polysaccharides |
| 01/17/1995 | CA2128139A1 Mdr reversal agents |
| 01/12/1995 | WO1995001425A1 Compositions comprising protein disulfide redox agents |
| 01/12/1995 | WO1995001420A2 A method of producing a protein disulfide redox agent |
| 01/12/1995 | WO1995001170A2 Use of phenethanolamine derivatives in the treatment of gastrointestinal disorders |
| 01/12/1995 | WO1995001096A1 Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology |
| 01/12/1995 | CA2166383A1 Pharmaceutical compositions and use thereof for treatment of neurological diseases and etiologically related symptomology |
| 01/11/1995 | EP0633029A2 Further improvements relating to drug delivery systems |
| 01/11/1995 | EP0632729A1 Anti-zona pellucida antibodies for delivery of therapeutic agents to the ovary |
| 01/11/1995 | CN1097142A Preparation method for tumor vaccine |
| 01/10/1995 | US5380754 Topical composition enhancing healing of viral lesions |
| 01/10/1995 | US5380747 Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| 01/05/1995 | WO1995000176A1 Compositions for treating hypoxia-associated ocular complications |
| 01/05/1995 | WO1995000175A1 Agent with influences hyperactive immunological effector cells |
| 01/05/1995 | WO1995000139A1 Compounds |
| 01/05/1995 | WO1995000041A1 Food and/or pharmaceutical composition having a low polyamine content, and therapeutical uses thereof |
| 01/05/1995 | WO1994021792A3 Inhibition of selected tumor growth with recombinant viral vectors |
| 01/05/1995 | CA2165481A1 Food and/or pharmaceutical composition having a low polyamine content, and therapeutical uses thereof |
| 01/03/1995 | US5378451 Topical medicinal pressurized aerosol compositions and method of preparation, method of use and article of manufacture thereof |
| 12/28/1994 | EP0630649A1 Combination of an inhibitor of inducible nitric oxide synthase (iNOS) and an antiinflammatory agent, e.g. a corticosteroid |
| 12/28/1994 | EP0630646A1 Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
| 12/28/1994 | EP0630263A1 Pharmaceutical composition having site-specific delivery |
| 12/28/1994 | EP0630254A1 Method of ophthalmic drug delivery |
| 12/28/1994 | EP0630251A1 Method and composition for suppression of side effects of anti-inflammatory drugs |
| 12/28/1994 | EP0630250A1 Pharmaceutical compositions containing monosialoganglioside gm 1? or a derivative thereof suitable for the treatment of parkinson's disease |
| 12/28/1994 | EP0630246A1 Estrogen/progestin/antiprogestin method and kit for oral contraception and regulating menses |
| 12/28/1994 | EP0630243A1 Combinations of parasympathomimetic agents with muscarinic antagonists for treating nicotine craving in smoking cessation |
| 12/28/1994 | EP0630240A1 Method for reducing intraocular pressure in the mammalian eye by administration of gamma aminobutyric acid (gaba) agonists |
| 12/27/1994 | US5376638 Methods for treating renin-related disorders with amylin antagonists |
| 12/27/1994 | US5376636 Method for promoting tissue repair and regeneration using PDGF and glucocorticoids |
| 12/27/1994 | US5375693 Methods and compositions for treating allergic disorders and other disorders metabolic derivatives of terfenadine |
| 12/22/1994 | WO1994029449A1 Human metabotropic glutamate receptors, nucleic acids encoding same and uses thereof |
| 12/22/1994 | WO1994028916A1 Release and mobilisation of haematopoietic cells |
| 12/22/1994 | WO1994028914A1 Assay and reagents for identifying anti-proliferative agents |
| 12/22/1994 | WO1994028911A1 COMPOSITIONS FOR USE IN THE REGULATION OF SUBNORMAL pH VALUES IN THE INTESTINAL TRACT AND FOR TREATMENT OF BOWEL DISEASES |
| 12/22/1994 | WO1994028909A1 Antineoplastic compositions and methods of use |
| 12/22/1994 | WO1994028902A1 Pyrazolopyrimidinones for the treatment of impotence |
| 12/22/1994 | WO1994028900A1 Methods and compositions for lowering intraocular pressure |
| 12/22/1994 | WO1994028898A1 H2-antagonists as immune stimulants in bacterial infections of cattle or swine |
| 12/22/1994 | WO1994028897A2 Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection |
| 12/22/1994 | WO1994028887A1 Synergistic anthelmintic compositions |
| 12/22/1994 | WO1994028870A1 Preparations containing silicon dioxide to improve the taste thereof |
| 12/22/1994 | WO1994028726A2 Method of treating retained pulmonary secretions |
| 12/22/1994 | WO1994028721A1 Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity |
| 12/22/1994 | WO1994022483A3 Prodrugs with enhanced penetration into cells |
| 12/22/1994 | CA2165344A1 Immune stimulants in bacterial infections |
| 12/22/1994 | CA2164733A1 Methods and compositions for lowering intraocular pressure |
| 12/22/1994 | CA2164641A1 Use of an mhc class i suppressor drug for the treatment of autoimmune diseases and transplantation rejection |